Physcion alleviates ulcerative colitis by upregulating SIRT3 to suppress PANoptosis via inhibition of the cGAS-STING pathway.

What To Know

The study used a standard chemical colitis model (DSS) in mice and intestinal epithelial cells in vitro to test physcion (PHY) and compared it with 5-ASA. Outcomes included disease severity, colon length, histology, barrier protein expression, measures of oxidative stress and inflammation, and markers of programmed cell death (PANoptosis).

PHY increased SIRT3 expression and reduced activation of the cGAS–STING pathway; knocking down SIRT3 removed PHY's protective effects, and co-immunoprecipitation supported an interaction between SIRT3 and cGAS. The work is preclinical (animal and cell experiments) and does not demonstrate safety or efficacy in humans with ulcerative colitis.

This identifies a possible mechanism (SIRT3 upregulation → cGAS–STING inhibition) that could guide future drug-discovery or biomarker research but is not clinical evidence that PHY is an effective treatment for patients.

Bottom line: Interesting mechanistic preclinical study suggesting physcion affects immune signaling and programmed cell death in UC models, but findings need replication and clinical testing before patient relevance is established.